Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06533553 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD
A Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Areteia Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT06533553: Active Phase 2 study of Chronic Obstructive Pulmonary Disease, sponsored by Areteia Therapeutics.
NCT06533553 is a Phase 2 study of Chronic Obstructive Pulmonary Disease that is active but no longer recruiting, run by Areteia Therapeutics. The registered enrollment target is 30 participants, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06533553, a Phase 2 study of Chronic Obstructive Pulmonary Disease, is active but no longer recruiting, sponsored by Areteia Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
Conditions Studied
Interventions
- DRUG Dexpramipexole Dihydrochloride
Study Locations (20)
California
- Research Site US-10001-008 - Newport Beach
- Research Site US-10001-022 - Northridge
- Research Site US-10001-016 - Westminster
North Carolina
- Research US-10001-010 - Charlotte
- Research Site US-10001-025 - Charlotte
- Research Site US-10001-007 - Gastonia
Missouri
- Research Site US-10001-005 - Saint Charles
- Research Site US-10001-001 - St Louis
Pennsylvania
- Research Site US-10001-002 - DuBois
- Research Site US-10001-013 - Philadelphia
Arkansas
- Research Site US-10001-017 - Conway
Florida
- Research Site US-10001-030 - Orlando
Illinois
- Research Site 10001-032 - Champaign
Indiana
- Research Site US-10001-021 - Hammond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-09 |
| Est. Completion | 2025-12 |
| Phase | Phase 2 |
What the registry record for NCT06533553 still lists
NCT06533553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,754-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Dexpramipexole Dihydrochloride is the first listed.
NCT06533553 names 20 study sites across 14 states, led by California, North Carolina, Missouri.
Frequently Asked Questions
What is clinical trial NCT06533553 about?
NCT06533553 is a clinical study titled "A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD". This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).
What is the current status of trial NCT06533553?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-07-09. Estimated completion is 2025-12.
What conditions does trial NCT06533553 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT06533553?
The interventions under investigation include: Dexpramipexole Dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT06533553?
This trial is sponsored by Areteia Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06533553 being conducted?
This trial has 20 study locations across Arkansas, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06533553's enrollment target sits among peer trials
30 67th of 86 higher than 16 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Biological Effects of Quercetin in COPD Phase II
RECRUITING · Phase 2
-
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD
RECRUITING · Phase 2
-
Breathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH
RECRUITING · Phase 2
-
Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI